Barry R. Davies

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 790 citations · Full text

Mtorc2 Substrate Akt, Cell Death, Pharmacotherapy +21

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley et al. · Molecular Cancer Therapeutics · 2012 · 453 citations

Pharmacotherapy, Cancer Biology, Tumor Biology +18

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action <i>in vivo</i> , pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Barry R. Davies, Armelle Logié, Jennifer S. McKay et al. · Molecular Cancer Therapeutics · 2007 · 387 citations

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada et al. · Nature Communications · 2019 · 327 citations · Full text

Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530

Tim P. Green, Mike Fennell, Robin Whittaker et al. · Molecular Oncology · 2009 · 254 citations · Full text